Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare inborn error of metabolism characterized by the presence of large amounts of trimethylamine in urine, sweat, and breath, resulting in a fishy body odor in affected individuals.
No HPO annotations are available for this condition.
Primary trimethylaminuria is characterized by fishy odor resulting from excess excretion of trimethylamine in the urine, breath, sweat, and reproductive fluids . No physical symptoms are associated with primary trimethylaminuria; affected individuals appear normal and healthy. However, the unpleasant odor characteristic of the disorder often results in social and psychological problems and can have serious effects on personal and working lives. These may include the following:
Diagnosis of primary trimethylaminuria has been discussed in detail and "best-practice" diagnostic guidelines have been summarized .
Primary trimethylaminuria should be suspected in individuals with the following clinical findings and family history. Body odor resembling that of rotten or decaying fish. Unoxidized trimethylamine (TMA) excreted in the urine, breath, sweat, and reproductive fluids is highly volatile and has a pungent ammoniac odor reminiscent of rotting fish . Note: Diagnosis of primary trimethylaminuria cannot be based on the examiners sense of smell due to the following:
No approved treatments are currently available for trimethylaminuria. An additional 2 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for trimethylaminuria, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for trimethylaminuria. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
14 publications have been identified in PubMed for trimethylaminuria. Research spans Case Report / Case Series (36%), Review / Meta-Analysis (21%), and Basic Science / Preclinical (21%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 36% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 12:58 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
European rare disease database
Source: GeneReviews — "Primary Trimethylaminuria"
Source: GeneReviews — "Primary Trimethylaminuria"
Molecular diagnosis can distinguish primary trimethylaminuria from trimethylaminuria not caused by genetic FMO3 deficiency . A classification scheme for the latter has been proposed .
Source: GeneReviews — "Primary Trimethylaminuria"
Biomarker and diagnostic research for trimethylaminuria has been reported in the published literature.
Designated
Exclusivity End |
|---|
Designation Status |
|---|
paracoccus aminovorans | paracoccus aminovorans | BioMe Inc. | 2025 | — | Designated |
N,N-dimethyl-N-(2-{[(2R,3R,4S,5R,6R)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}ethyl)cyclopropylammonium | N,N-dimethyl-N-(2-{[(2R,3R,4S,5R,6R)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}ethyl)cyclopropylammonium | Kintai Therapeutics, Inc. | 2020 | — | Withdrawn |
Gene therapy approaches for trimethylaminuria have been reported in the published literature.
No clinical practice guidelines for primary trimethylaminuria have been published.
To establish the extent of disease and needs in an individual diagnosed with primary trimethylaminuria, the following evaluations (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Determine the urinary ratio of trimethylamine (TMA) N-oxide to total TMA on a normal diet. The general rule is that the lower the ratio the more severe the disorder:
Ratios of 70%-89% are classified as mild.
Ratios lower than 70% are classified as severe.
Assess social issues associated with body odor. These may include harassment, bullying, discrimination, negative self-image, social isolation, and relationship problems . An assessment tool for evaluation of social and mental health effects of the disorder has been proposed .
Consult with a medical geneticist, certified genetic counselor, or certified advanced genetic nurse to inform affected individuals and their families about the nature, mode of inheritance, and implications of primary trimethylaminuria in order to facilitate medical and personal decision making.
Strategies for the treatment of primary trimethylaminuria summarized in this section are reviewed by . Restriction of dietary trimethylamine and its precursors. In some instances the disorder can be successfully managed by dietary restriction of precursors of trimethylamine.
Source: GeneReviews — "Primary Trimethylaminuria"
1 trial found
Research summaries |
3 |
21% |
Laboratory research | 3 | 21% |
New treatment approaches | 2 | 14% |
Testing and diagnosis research | 1 | 7% |
Gao W (2026). [PMID: 41789564](https://pubmed.ncbi.nlm.nih.gov/41789564/). *ACS Sens*. [Basic Science / Preclinical]
DeVito VL (2026). [PMID: 41872195](https://pubmed.ncbi.nlm.nih.gov/41872195/). *NPJ Syst Biol Appl*. [Gene Therapy / Novel Therapeutics]
Woo AYM (2026). [PMID: 41728982](https://pubmed.ncbi.nlm.nih.gov/41728982/). *mBio*. [Diagnostic / Biomarker]
Malinosky HR (2025). [PMID: 41056116](https://pubmed.ncbi.nlm.nih.gov/41056116/). *Cutis*. [Review / Meta-Analysis]
Salahi A (2025). [PMID: 40028749](https://pubmed.ncbi.nlm.nih.gov/40028749/). *Vet Med Sci*. [Review / Meta-Analysis]
Knapp M (2025). [PMID: 40636240](https://pubmed.ncbi.nlm.nih.gov/40636240/). *Eur J Case Rep Intern Med*. [Case Report / Case Series]
Resende MM (2025). [PMID: 40125190](https://pubmed.ncbi.nlm.nih.gov/40125190/). *Cureus*. [Case Report / Case Series]
Shimizu M (2025). [PMID: 40691058](https://pubmed.ncbi.nlm.nih.gov/40691058/). *Biol Pharm Bull*. [Basic Science / Preclinical]
Giannini G (2025). [PMID: 41132530](https://pubmed.ncbi.nlm.nih.gov/41132530/). *Front Pharmacol*. [Basic Science / Preclinical]
Cini E (2025). [PMID: 40907381](https://pubmed.ncbi.nlm.nih.gov/40907381/). *Eur J Med Chem*. [Gene Therapy / Novel Therapeutics]